Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | GAA | P10253 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10137516 | 0.88 | MAPT (0.34) | MAPTALDH1A1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL21865920 | 0.80 | MAPT (0.41) | MAPTALDH1A1KMT2A | |
| SCHEMBL21865774 | 0.80 | MAPT (0.41) | MAPTALDH1A1KMT2A | |
| SCHEMBL14376312 | 0.78 | MAPT (0.54) | MAPTALDH1A1SMN1; SMN2TSHR | |
| SCHEMBL14065598 | 0.78 | MAPT (0.54) | MAPTALDH1A1SMN1; SMN2TSHR | |
| SCHEMBL14065593 | 0.78 | MAPT (0.54) | MAPTALDH1A1SMN1; SMN2TSHR | |
| SCHEMBL426312 | 0.78 | MAPT (0.57) | MAPTALDH1A1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL13130106 | 0.76 | ALDH1A1 (0.55) | ALDH1A1SMN1; SMN2TSHRKDM4E | |
| SCHEMBL13473844 | 0.75 | SLC6A3 (0.53) | MAPT | |
| SCHEMBL12592383 | 0.75 | SLC6A3 (0.53) | MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110092704-A1 | Preparation of triazospiro compounds | EURO-CELTIQUE S.A. (LU) | 2011-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110092704-A1 | Preparation of triazospiro compounds | CBR1, TBXA2R, CBR3 | MAPT 3552/4885ALDH1A1 495/4885SMN1; SMN2 3706/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.